An investigation into the efficacy of complement inhibitors (such as Eculizumab [51] or Compstatin [52]), and plasminogen activators specifically for T-PA, combined with Vitamin-D supplementation to alleviate symptoms in patients with severe/acute COVID-19, warrant exploration. Here, PLG is linked to COVID-19.